PKC activators were originally considered for Alzheimer's disease (Talman et al., 2016) and nanobodies that act as allosteric activators of leucine-rich repeat kinase 2 (LRRK2) have been discussed in the context of Parkinson's disease (Singh et al., 2022). Here, LRRK2 is linked to early-onset autosomal dominant Alzheimer disease.